Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy

Ronald Moura Rodrigues, Monserrat Plana, Felipe Garcia, Luisa Zupin, Louise Kuhn, Sergio Crovella

Research output: Contribution to journalArticle

Abstract

We performed a retrospective genome-wide association study in HIV-infected individuals who were treated with dendritic cell-based immunotherapy in clinical trials performed by two research groups (Spain and Brazil). We aimed to identify host genetic variants influencing treatment response. The Illumina Human Core Exome 12 v 1.0 Bead Chip with over 250,000 markers was used to analyze genetic factors affecting treatment response. Additionally, we performed a meta-analysis of the results obtained from Spanish and Brazilian patients. We identified a genetic variation (rs7935564 G allele) in TRIM22 gene, which encodes TRIM22 protein acting like a HIV restriction factor, as being associated with good response to dendritic cell-based immunotherapy. We then verified the impact of TRIM22 rs7935564 SNP in susceptibility to HIV infection and disease progression by assessing the influence of biogeographic ancestry in the distribution of allelic and genotype frequencies in three populations from Italy, Brazil and Zambia. TRIM22 rs7935564 genotyping indicated association of G rs7935564 allele with long-term non-progression of HIV disease in Italian patients, thus corroborating our hypothesis that it is involved as a restriction factor in dendritic cell-based immunotherapy response. TRIM22 rs7935564 polymorphism was associated with good response to dendritic cell-based immunotherapy. We hypothesize that in selecting patients for treatment, there is a possible bias related to the natural presence of restriction factors that are genetically determined and could influence final outcome of therapy.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalImmunologic Research
DOIs
Publication statusAccepted/In press - Oct 4 2016

Fingerprint

Immunotherapy
Dendritic Cells
HIV
Genome
Brazil
Alleles
Exome
Zambia
Genome-Wide Association Study
Therapeutics
Spain
Italy
Statistical Factor Analysis
HIV Infections
Single Nucleotide Polymorphism
Disease Progression
Meta-Analysis
Genotype
Clinical Trials
Research

Keywords

  • Dendritic cells
  • Genome-wide
  • HIV
  • Immune-therapy
  • SNPs
  • TRIM22

ASJC Scopus subject areas

  • Immunology

Cite this

Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy. / Moura Rodrigues, Ronald; Plana, Monserrat; Garcia, Felipe; Zupin, Luisa; Kuhn, Louise; Crovella, Sergio.

In: Immunologic Research, 04.10.2016, p. 1-9.

Research output: Contribution to journalArticle

Moura Rodrigues, Ronald ; Plana, Monserrat ; Garcia, Felipe ; Zupin, Luisa ; Kuhn, Louise ; Crovella, Sergio. / Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy. In: Immunologic Research. 2016 ; pp. 1-9.
@article{5dd232cf19044d1688673449b315978e,
title = "Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy",
abstract = "We performed a retrospective genome-wide association study in HIV-infected individuals who were treated with dendritic cell-based immunotherapy in clinical trials performed by two research groups (Spain and Brazil). We aimed to identify host genetic variants influencing treatment response. The Illumina Human Core Exome 12 v 1.0 Bead Chip with over 250,000 markers was used to analyze genetic factors affecting treatment response. Additionally, we performed a meta-analysis of the results obtained from Spanish and Brazilian patients. We identified a genetic variation (rs7935564 G allele) in TRIM22 gene, which encodes TRIM22 protein acting like a HIV restriction factor, as being associated with good response to dendritic cell-based immunotherapy. We then verified the impact of TRIM22 rs7935564 SNP in susceptibility to HIV infection and disease progression by assessing the influence of biogeographic ancestry in the distribution of allelic and genotype frequencies in three populations from Italy, Brazil and Zambia. TRIM22 rs7935564 genotyping indicated association of G rs7935564 allele with long-term non-progression of HIV disease in Italian patients, thus corroborating our hypothesis that it is involved as a restriction factor in dendritic cell-based immunotherapy response. TRIM22 rs7935564 polymorphism was associated with good response to dendritic cell-based immunotherapy. We hypothesize that in selecting patients for treatment, there is a possible bias related to the natural presence of restriction factors that are genetically determined and could influence final outcome of therapy.",
keywords = "Dendritic cells, Genome-wide, HIV, Immune-therapy, SNPs, TRIM22",
author = "{Moura Rodrigues}, Ronald and Monserrat Plana and Felipe Garcia and Luisa Zupin and Louise Kuhn and Sergio Crovella",
year = "2016",
month = "10",
day = "4",
doi = "10.1007/s12026-016-8875-x",
language = "English",
pages = "1--9",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",

}

TY - JOUR

T1 - Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy

AU - Moura Rodrigues, Ronald

AU - Plana, Monserrat

AU - Garcia, Felipe

AU - Zupin, Luisa

AU - Kuhn, Louise

AU - Crovella, Sergio

PY - 2016/10/4

Y1 - 2016/10/4

N2 - We performed a retrospective genome-wide association study in HIV-infected individuals who were treated with dendritic cell-based immunotherapy in clinical trials performed by two research groups (Spain and Brazil). We aimed to identify host genetic variants influencing treatment response. The Illumina Human Core Exome 12 v 1.0 Bead Chip with over 250,000 markers was used to analyze genetic factors affecting treatment response. Additionally, we performed a meta-analysis of the results obtained from Spanish and Brazilian patients. We identified a genetic variation (rs7935564 G allele) in TRIM22 gene, which encodes TRIM22 protein acting like a HIV restriction factor, as being associated with good response to dendritic cell-based immunotherapy. We then verified the impact of TRIM22 rs7935564 SNP in susceptibility to HIV infection and disease progression by assessing the influence of biogeographic ancestry in the distribution of allelic and genotype frequencies in three populations from Italy, Brazil and Zambia. TRIM22 rs7935564 genotyping indicated association of G rs7935564 allele with long-term non-progression of HIV disease in Italian patients, thus corroborating our hypothesis that it is involved as a restriction factor in dendritic cell-based immunotherapy response. TRIM22 rs7935564 polymorphism was associated with good response to dendritic cell-based immunotherapy. We hypothesize that in selecting patients for treatment, there is a possible bias related to the natural presence of restriction factors that are genetically determined and could influence final outcome of therapy.

AB - We performed a retrospective genome-wide association study in HIV-infected individuals who were treated with dendritic cell-based immunotherapy in clinical trials performed by two research groups (Spain and Brazil). We aimed to identify host genetic variants influencing treatment response. The Illumina Human Core Exome 12 v 1.0 Bead Chip with over 250,000 markers was used to analyze genetic factors affecting treatment response. Additionally, we performed a meta-analysis of the results obtained from Spanish and Brazilian patients. We identified a genetic variation (rs7935564 G allele) in TRIM22 gene, which encodes TRIM22 protein acting like a HIV restriction factor, as being associated with good response to dendritic cell-based immunotherapy. We then verified the impact of TRIM22 rs7935564 SNP in susceptibility to HIV infection and disease progression by assessing the influence of biogeographic ancestry in the distribution of allelic and genotype frequencies in three populations from Italy, Brazil and Zambia. TRIM22 rs7935564 genotyping indicated association of G rs7935564 allele with long-term non-progression of HIV disease in Italian patients, thus corroborating our hypothesis that it is involved as a restriction factor in dendritic cell-based immunotherapy response. TRIM22 rs7935564 polymorphism was associated with good response to dendritic cell-based immunotherapy. We hypothesize that in selecting patients for treatment, there is a possible bias related to the natural presence of restriction factors that are genetically determined and could influence final outcome of therapy.

KW - Dendritic cells

KW - Genome-wide

KW - HIV

KW - Immune-therapy

KW - SNPs

KW - TRIM22

UR - http://www.scopus.com/inward/record.url?scp=84990817474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990817474&partnerID=8YFLogxK

U2 - 10.1007/s12026-016-8875-x

DO - 10.1007/s12026-016-8875-x

M3 - Article

AN - SCOPUS:84990817474

SP - 1

EP - 9

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

ER -